A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC

被引：2
|
作者：
Bergstrom, Donald [1 ]
Bodyak, Natalya [1 ]
Yurkovetskiy, Alex [1 ]
Poling, Laura [1 ]
Yin, Mao [1 ]
Protopopova, Marina [1 ]
Devit, Mike [1 ]
Qin, Liuliang [1 ]
Gumerov, Dmitry [1 ]
Ter-Ovanesyan, Elena [1 ]
Mosher, Rebecca [1 ]
Lowinger, Timothy [1 ]
机构：
[1] Mersana Therapeut, Cambridge, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Novel Therapies; Antibody-drug conjugate; Adenocarcinoma; Targeted chemotherapy;
D O I：
10.1016/j.jtho.2016.11.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA09.10
引用
收藏
页码：S396 / S397
页数：2
相关论文
共 50 条
  • [1] Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
    Mosher, Rebecca
    Poling, Laura
    Qin, LiuLiang
    Bodyak, Natalya
    Bergstrom, Donald
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models
    Schreiber, Anna R.
    Nguyen, Anna
    Bagby, Stacey M.
    Yacob, Betelehem
    Quackenbush, Kevin
    Guy, Joe L.
    Crowell, Thomas
    Stringer, Bradley
    Danaee, Hadi
    Kalebic, Thea
    Messersmith, Wells A.
    Arcaroli, John J.
    Pitts, Todd M.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [3] Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
    Meric-Bernstam, Funda
    Yuca, Erkan
    Evans, Kurt W.
    Zhao, Ming
    Maejima, Takanori
    Karibe, Tsuyoshi
    Raso, Maria Gabriela
    Tang, Ximing
    Zheng, Xiaofeng
    Rizvi, Yasmeen Qamar
    Akcakanat, Argun
    Scott, Stephen M.
    Wang, Bailiang
    Byers, Lauren A.
    Tripathy, Debu
    Okajima, Daisuke
    Damodaran, Senthil
    CLINICAL CANCER RESEARCH, 2025, 31 (03) : 573 - 587
  • [4] ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
    Smith, Roger A.
    Zammit, David J.
    Damle, Nitin K.
    Usansky, Helen
    Reddy, Sanjeeva P.
    Lin, Jun-Hsiang
    Mistry, Mahesh
    Rao, Niranjan S.
    Denis, Louis J.
    Gupta, Sandeep
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1327 - 1337
  • [5] Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
    Wu, Chi-Heng
    Wang, Linlin
    Yang, Chen-Yen
    Wen, Kwun Wah
    Hinds, Brian
    Gill, Ryan
    McCormick, Frank
    Moasser, Mark
    Pincus, Laura
    Ai, Weiyun Z.
    BLOOD ADVANCES, 2022, 6 (07) : 2290 - 2302
  • [6] Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b
    Horsley, Elizabeth
    Jabeen, Asma
    Veillard, Nicolas
    Havenith, Karin
    Janghra, Narinder
    Alves, Pedro
    Oblette, Cecile
    Kirby, Ian
    Hogg, Paul W.
    Zammarchi, Francesca
    de Haan, Lolke
    van Berkel, Patrick
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Patient-derived tumor xenograft models for melanoma drug discovery
    Harris, Antoneicka L.
    Joseph, Richard W.
    Copland, John A.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (09) : 895 - 906
  • [8] The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
    Bodyak, Natalya D.
    Mosher, Rebecca
    Yurkovetskiy, Aleksandr, V
    Yin, Mao
    Bu, Charlie
    Conlon, Patrick R.
    Demady, Damon R.
    DeVit, Michael J.
    Gumerov, Dmitry R.
    Gurijala, Venu R.
    Lee, Winnie
    McGillicuddy, Dennis
    Park, Peter U.
    Poling, Laura L.
    Protopova, Marina
    Qin, LiuLiang
    Stevenson, Cheri A.
    Ter-Ovanesyan, Elena
    Uttard, Alex
    Xiao, Dongmei
    Xu, Jian
    Xu, Ling
    Bergstrom, Donald A.
    Lowinger, Timothy B.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) : 896 - 905
  • [9] Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma
    Van Renterghem, Britt
    Wozniak, Agnieszka
    Castro, Patricia Garrido
    Franken, Patrick
    Pencheva, Nora
    Sciot, Raf
    Schoffski, Patrick
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [10] ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models
    Vaisitti, Tiziana
    Arruga, Francesca
    Vitale, Nicoletta
    Lee, Thanh-Trang
    Ko, Mira
    Chadburn, Amy
    Braggio, Esteban
    Di Napoli, Arianna
    Iannello, Andrea
    Allan, John N.
    Miller, Langdon L.
    Lannutti, Brian J.
    Furman, Richard R.
    Jessen, Katti A.
    Deaglio, Silvia
    BLOOD, 2021, 137 (24) : 3365 - 3377
12345